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Abstract (249/250 max) 
Purpose: This Phase 1, open-label study (Study 1, D3610C00001; NCT01226316) was 
the first-in-human evaluation of oral AZD5363, a selective pan-AKT inhibitor, in patients 
with advanced solid malignancies. The objectives were to investigate the safety, 
tolerability and pharmacokinetics of AZD5363, define a recommended dosing schedule, 
and evaluate preliminary clinical activity.  
 
Experimental design: Patients were aged ≥18 years with WHO performance status 0–
1. Dose escalation was conducted within separate continuous and intermittent (4 
days/week [4/7] or 2 days/week [2/7]) schedules with safety, pharmacokinetic and 
pharmacodynamic analyses. Expansion cohorts of approximately 20 patients each 
explored AZD5363 activity in PIK3CA-mutant breast and gynecologic cancers.  
 
Results: Maximum tolerated doses were 320 mg, 480 mg and 640 mg for continuous 
(n=47), 4/7 (n=21) and 2/7 (n=22) schedules, respectively. Dose-limiting toxicities were 
rash and diarrhea for continuous, hyperglycemia for 2/7, and none for 4/7. Common 
adverse events were diarrhea (78%) and nausea (49%) and, for CTCAE grade ≥3 
events, hyperglycemia (20%). The recommended Phase 2 dose (480 mg bid, 4/7 
intermittent) was assessed in PIK3CA-mutant breast and gynecologic expansion 
cohorts: 46% and 56% of patients, respectively, showed a reduction in tumor size, with 
RECIST responses of 4% and 8%. These responses were less than the pre-specified 
20% response rate; therefore, the criteria to stop further recruitment to the PIK3CA 
cohort were met.   
  
Conclusions: At the recommended Phase 2 dose, AZD5363 was well tolerated and 
achieved plasma levels and robust target modulation in tumors. Proof-of-concept 
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responses were observed in patients with PIK3CA-mutant cancers treated with 
AZD5363.  
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Statement of translational relevance (144/150 max) 
AZD5363 is a potent, selective inhibitor of AKT, a key node in the PI3K/AKT/mTOR 
pathway that is activated in a wide range of malignancies. In vivo, AZD5363 inhibited 
tumor growth in xenograft models. Preclinically, sensitivity to AZD5363 has been 
strongly related to the presence of PIK3CA mutations, which are relatively common in 
breast and gynecologic cancers. Our study, the first-in-human study of AZD5363, 
showed that at an identified recommended Phase 2 dose, AZD5363 was well tolerated 
and achieved plasma levels and robust target modulation in tumors. The study is also 
the first report of a biomarker-stratified cohort (PIK3CA mutations in breast and 
gynecologic cancers) of patients treated with an AKT inhibitor. Results suggest that 
future efforts in developing this class of drugs for the treatment of solid tumors, including 
PIK3CA-mutated breast and gynecologic cancers, will need to be in combination with 
other anticancer drugs.   
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Introduction  
AKT is a serine/threonine protein kinase that functions as a key node in the 
phosphatidylinositol-3-kinase (PI3K)/AKT network (also known as the PI3K/AKT/mTOR 
pathway), with a fundamental role in cell survival and proliferation (1). AKT is over-
expressed or activated in a wide range of solid and hematologic malignancies, and 
aberrant AKT signaling is also associated with resistance to established cancer 
therapies, as well as advanced disease and/or poor prognosis (2).  
 
AZD5363 is a potent, selective inhibitor of the kinase activity of all three AKT isoforms 
(AKT1, -2, and -3) (3). In vitro, AZD5363 inhibited tumor cell proliferation and 
phosphorylation of the AKT substrates PRAS40 and GSK3β, as well as the downstream 
pathway protein S6. In vivo, AZD5363 inhibited tumor growth in xenograft models and 
remained pharmacodynamically active for at least 24 hours (3). Preclinically, sensitivity 
to AZD5363 has been strongly related to the presence of PIK3CA mutations (4, 5), a 
trend that has also been observed with other inhibitors of the PI3K/AKT/mTOR pathway 
(6). PIK3CA mutations are found in breast and gynecologic cancers, and evaluation of 
AZD5363 in these settings is warranted (1). 
 
We report the first-in-human study of AZD5363, which evaluated safety, 
pharmacokinetics (PK), and pharmacodynamics (PD) in three schedules and 
recommended a Phase 2 dose for future development. We also report the first 
evaluation of an AKT inhibitor used as a single agent in a PIK3CA-mutated breast and 
ovarian cancer population. 
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Materials and methods 
Study design  
This is a multipart, Phase 1, open-label, multicenter study of oral AZD5363 in patients 
with advanced solid malignancies (Study 1; NCT01226316; Supplementary Figure 1). 
Parts A and B were, respectively, the dose-escalation and -expansion phase. Part C 
focused on an expansion cohort of patients with a PIK3CA tumor mutation. An additional 
expansion cohort of patients with an AKT1 tumor mutation (Part D) will be reported 
separately. 
 
Patients 
All patients were aged ≥18 years with a WHO performance status of 0–1 and minimum 
life expectancy of 12 weeks. Patients in Part C had advanced estrogen receptor positive 
(ER+) or human epidermal growth factor receptor 2 positive (HER2+) breast cancer 
(based on local testing) (7) or gynecologic (ovarian, cervical, or endometrial) cancer, 
with any PIK3CA mutation detected by local or central testing, and at least one 
measurable lesion. Additionally for Part C, where known, other solid tumors (ie not 
breast or gynecologic) should be negative for mutations of KRAS, NRAS, HRAS, and 
BRAF. Key exclusion criteria are summarized in the supplementary material. 
 
Study objectives 
The primary objective of Parts A and B was to investigate the safety and tolerability of 
oral AZD5363 and to define a recommended monotherapy dose and schedule for further 
clinical evaluation. Secondary objectives included PK evaluation of AZD5363 and 
preliminary assessment of antitumor activity. The objectives of Part C were to investigate 
safety, tolerability, PK, and antitumor activity of the defined AZD5363 dosing schedule in 
patients with ER+ or HER2+ breast cancer or gynecologic cancer harboring a PIK3CA 
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mutation. Exploratory objectives of Study 1 overall included the characterization of the 
PD effects of AZD5363 in paired tumor biopsies and in platelet-rich plasma (PRP; Parts 
A and B). 
 
Study design and treatment 
Part A – dose escalation 
Cohorts of 3–6 unselected patients received a single starting dose of 80 mg of AZD5363 
and, after a 3- to 7-day washout, AZD5363 twice daily (bid). The dosing cycle was 21 
days, excluding the run-in dose. Upon reaching a continuous dose considered 
appropriate by the Safety Review Committee (SRC), two intermittent dosing schedules 
were initiated in parallel: 4 days on, 3 days off every week (4/7) and 2 days on, 5 days 
off every week (2/7). Dose escalation continued for each schedule until a non-tolerated 
dose was attained (≥2/6 dose-limiting toxicities [DLTs]) and a maximum tolerated dose 
(MTD) was identified. Definitions of DLTs are provided in the supplementary material. 
 
Part B – dose expansion 
To confirm selection of the recommended dose for the schedules explored in Part A, the 
safety profile and tolerability were evaluated in up to nine additional unselected patients. 
The SRC also reviewed safety and tolerability data on an ongoing basis. 
 
Part C – expansion in PIK3CA-mutant patients 
Two cohorts of patients with PIK3CA-mutant ER+ or HER2+ breast cancers (Cb cohort) 
or gynecologic cancers (Cg cohort) received the recommended dose and schedule 
identified from Parts A and B. Each cohort permitted a maximum of 120 patients; 
recruitment to each cohort was prospectively contingent on positive interim efficacy and 
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safety data reviews after 20 and 40 patients had the opportunity to be followed for ≥12 
weeks.  
 
The trial (Study 1; NCT01226316) was performed in accordance with the principles of the 
Declaration of Helsinki, Good Clinical Practice, and the AstraZeneca policy on bioethics 
(8). The local ethics committee or independent review board at each investigator site 
approved the protocol prior to study commencement. All patients provided written 
informed consent prior to study participation. 
 
Assessments  
Safety and tolerability were assessed by continual monitoring of adverse events (AEs) 
according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 
Serial venous blood samples for PK assessment of AZD5363 in plasma were taken up 
to 48 hours post-dose in Part A, and up to 1 week after the last day of weekly dosing in 
Part B. Evaluated PK parameters included area under the plasma concentration–time 
curve (AUC), maximum plasma concentration (Cmax), time to Cmax (tmax), and apparent 
terminal half-life (t1/2).  
 
Blood samples were obtained at scheduled time points to assess changes in PD 
biomarkers of AKT inhibition (such as p-GSK3β and pPRAS40) in PRP using solid-
phase enzyme-linked immunosorbent Mesoscale Discovery multiplex assays. Paired 
tumor biopsies (pre- and on treatment) from consenting patients participating in this 
study and in a study of AZD5363 in Japanese patients (Study 4; NCT01353781) (9) 
were pooled. Pooling provided an adequately sized cohort to assess proof of 
mechanism (PoM) for the measurement of changes in AKT pathway effectors, including 
p-AKT, p-PRAS40, p-GSK3β, and Foxo3a/Foxo1 localization, by immunohistochemistry 
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(10). Details on the collection and analysis of PRP and tumor tissue samples, and 
mutation analyses in tissue and circulating free DNA (ctDNA), are described in the 
supplementary material. 
 
To determine antitumor activity, tumor assessments were categorized based on 
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Percentage change 
in tumor size was determined at each visit by the percentage change in the sum of the 
diameters of target lesions compared with baseline. 
 
Statistical methods 
All patients who received ≥1 dose of AZD5363 were included in the safety analyses. 
Safety and tolerability were assessed in terms of AEs, serious AEs, deaths, laboratory 
data, vital signs, electrocardiogram (ECG) changes, left ventricular ejection fraction, and 
abnormalities of glucose metabolism. All patients who provided appropriate samples 
were assessed for PK and PD. Standard non-compartmental PK parameters were 
calculated using Phoenix WinNonlin version 6 software. Modeling and simulation 
were applied to emerging safety, PK, and PD data to provide an understanding of any 
dose exposure–response relationships, and to support dose-escalation and dosing-
schedule decisions. Preclinical PK, PD, and efficacy data were used to define PoM 
thresholds for the reduction of phosphorylation of GSK3β and PRAS40 to provide 
confidence that on-target PoM was achieved at tolerable doses (described in the 
supplementary material).  
 
The pre-defined formal trigger in Part C to stop the study for futility was four or fewer 
responses by RECIST once 20 patients in each cohort had the opportunity to be 
followed for 12 weeks, ie a ≤10% chance that the true proportion of RECIST responses 
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was ≥40%. Antitumor activity was assessed by response rate, with two-sided Clopper–
Pearson confidence intervals to provide probability statements of the efficacy signal.  
 
Role of the funding source 
This study was sponsored by AstraZeneca. The study funder, AstraZeneca, provided 
organizational support, obtained data, did the analyses, and had a role in data 
interpretation and writing of the manuscript. All authors had access to study data. The 
corresponding author (UB) had unrestricted access to all study data and had final 
responsibility for the decision to submit for publication. 
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Results 
Dose escalation and expansion (Parts A and B) 
Patients  
A total of 90 patients were assigned to treatment; 47, 21, and 22 received AZD5363 in 
the continuous, 4/7, and 2/7 intermittent schedules, respectively. Patient demographic 
and baseline clinical characteristics are shown in Table 1. The most common cancers 
were rectal/colorectal (29%). By the time of the final analysis, all 90 patients had ceased 
study medication, most commonly for progression of the disease under investigation 
(64%).  
 
Safety and tolerability 
The MTDs of the continuous, 4/7, and 2/7 schedules were 320, 480, and 640 mg bid, 
respectively (Supplementary Figure 2). For the continuous dosing schedule, the 600 mg 
bid cohort was not tolerated: 2/2 patients experienced DLTs (one event of grade 3 rash 
and one of grade 4 rash). An intermediate dose level of 480 mg bid was, therefore, 
investigated; in this cohort, 4/6 patients experienced DLTs (three events of grade 3 rash 
and one of grade 3 diarrhea). At a further lower dose level of 320 mg bid, 0/12 patients 
experienced DLTs, and this dose was considered the MTD for the continuous schedule. 
In the 4/7 intermittent dosing schedule, no DLTs were observed in the 480 mg bid (n=11) 
and 640 mg bid (n=10) cohorts; however, based on the presence of chronic toxicities 
such as rash and diarrhea observed outside the first 21-day cycle DLT window, the 
lower dose of 480 mg bid was considered tolerable and appropriate for chronic use with 
4/7 dosing. In the 2/7 intermittent dosing schedule, at 800 mg bid, 3/14 patients had 
DLTs (two events of grade 4 hyperglycemia and one of grade 3 hyperglycemia); again, 
considering observed chronic toxicities, a dose of 640 mg bid was explored. In this 
cohort, DLTs were observed in 1/8 patients (one event of grade 4 hyperglycemia), and 
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the 640 mg bid dose was considered tolerable (Supplementary Figure 2). All DLTs were 
reversible; no events of ketoacidosis were reported in patients with hyperglycemia. Two 
patients remained on AZD5363 for longer than 6 months (one patient on the 480 mg bid 
4/7 schedule and one patient on the 800 mg bid 2/7 schedule); the median duration of 
exposure was 44 days (range 1‒507). 
 
The most frequently reported AEs across all dosing schedules were gastrointestinal 
events (diarrhea, vomiting, nausea) (Table 2). Grade ≥3 AEs were experienced by 56 
patients (62%), most commonly hyperglycemia (n=18; 20%), diarrhea (n=13; 14%) and 
maculopapular rash (n=10; 11%) (Supplementary Table 5). Overall, 21 patients (23%) 
had an AE leading to discontinuation; the most common (≥2%) were diarrhea (8%), 
maculopapular rash (8%), and dehydration (2%). AEs leading to dose interruption or 
reduction were experienced by 29 (32%) and 21 (23%) patients, respectively. No AEs 
resulted in death, and seven patients died as a result of the disease under investigation. 
All 90 patients had blood glucose levels above the upper limit of normal at some point 
following initiation of therapy with AZD5363 – this developed within the first 2 weeks of 
multiple dosing in the majority of patients (77%). Grade 3 elevations (>13.9 mmol/L) 
were seen in 33 patients (37%). No other clinically important trends were observed in 
laboratory parameters, vital signs, physical findings, or ECG changes. 
 
Pharmacokinetics and pharmacodynamics 
Plasma concentrations of AZD5363 showed a median tmax of 2 hours (range 0.5‒6), with 
a terminal half-life of approximately 10 hours (range 7‒15) after the first dose. Exposure 
was approximately dose proportional for doses of 80–800 mg (Figure 1A). Multiple-dose 
PK profiles are shown in Figure 1B. The geometric mean PK exposures on Day 4 of the 
480 mg dose in the 4/7 schedule were: Cmax 1426 ng/mL; minimum plasma 
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concentration (Cmin) 357 ng/mL; and AUC 7952 ng·h/mL. Intermittent dose schedules 
exceeded the predicted efficacious Cmin estimated from xenograft tumors 
(supplementary material) (11). The mean fraction of the AZD5363 dose excreted 
unchanged in urine ranged from 4% to 7%. Changes in PRAS40 and GSK3β 
phosphorylation in PRP occurred across multiple dose levels and precluded any 
definitive conclusion regarding a dose–response relationship. In patients treated with the 
recommended Phase 2 dose and schedule (480 mg bid, 4/7 intermittent), a reduction of 
>30% in pPRAS40 and pGSK3β compared with baseline at 4 hours after the single dose 
of AZD5363 was observed (Figure 2A), with return to baseline levels approximately 10 
hours post-treatment (Figure 2B).  
 
Additional observations indicating PD activity of AZD5363 included an increase in 
plasma and blood glucose, insulin, and C-peptide levels. In particular, blood glucose 
levels increased across all cohorts and peaked approximately 4 hours after each dose 
(Supplementary Figure 5), returning towards pre-dose baseline levels 8 hours post-dose, 
with a clear dose–response relationship in terms of the magnitude of peak glucose levels 
observed (not shown).  
 
Proof of target engagement in tumor tissue 
Evaluable paired tumor biopsies from 12 patients (nine from the current study [Study 1; 
NCT01226316] and three from Study 4 (AstraZeneca study D3610C00004) 
[NCT01353781]) (9) who received a range of doses and schedules were evaluated to 
assess PoM. Over 50% inhibition of pPRAS40 was seen in 4/12 paired biopsies and 
>30% decrease in pGSK3β was observed in 6/11 paired biopsies; 4/11 samples met 
both endpoints (Figure 3A and 3B, Supplementary Table 1). Downregulation of PD 
biomarkers was observed >4 hours post-dose, including with intermittent dosing 
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(Supplementary Table 1). These data are consistent with the PD response achieved in 
BT474c xenografts grown in nude mice at a dose that resulted in significant tumor 
growth inhibition (Supplementary Figure 4). AZD5363 treatment also increased 
phosphorylation levels of AKT (consistent with ATP competitive mechanism of action), 
inhibited phosphorylation of 4EBP1, and resulted in inhibition of Foxo nuclear 
translocation (Figure 3A) (10). In the five patients treated with the recommended Phase 
2 dose and schedule (480 mg bid, 4/7 intermittent), the average percentage decrease 
from baseline for pPRAS40 (59%) and pGSK3b (67%) exceeded the PD response 
required for preclinical efficacy (Figure 3B). 
 
Recommended Phase 2 dose  
Based on preclinical models, the trough plasma concentrations achieved at the tolerable 
dose of 320 mg bid on a continuous schedule exceeded those required for xenograft 
activity (Supplementary Figure 4). Further modeling has suggested that a 1.3- and 1.7-
fold dose level over continuous dosing would be efficacious when administered on the 
4/7 and 2/7 schedules, respectively (11). Based on the combination of tolerability profile, 
PK profile achieved, evidence of target engagement in normal and tumor tissue, and 
modeling predictions of efficacy, the dose of 480 mg bid on a 4/7 intermittent schedule 
was declared as the recommended Phase 2 dose. The dose level of 640 mg bid 2/7 was 
also tolerable, achieved adequate PK exposure, showed evidence of target modulation 
in PRP (tumor biopsy data were not available in this schedule), and was predicted to be 
efficacious from modeling of preclinical data. This schedule could be of use in 
combination studies in the future.  
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Antitumor activity 
There was limited evidence that AZD5363 induced tumor shrinkage in the unselected 
patient population in Parts A and B. A total of 27 (30%) and six (7%) patients achieved 
stable disease for ≥6 and ≥12 weeks, respectively. A PIK3CA mutation was detected in 
12/67 patients with archival tumor tissue suitable for exploratory Sequenom™ analysis, 
of whom 8/12 received an AZD5363 dose ≥400 mg. Additionally, 0/68 tumors harbored 
an AKT1 E17K mutation, 29% (20/68) harbored a RAS mutation (18 KRAS and 2 
NRAS), and 25% (3/12) of the PIK3CA-mutant tumors had concurrent KRAS mutation 
(Figure 4A). In particular, the patient who achieved a RECIST partial response (PIK3CA 
E545K mutant) had cervical cancer with hepatic and lymph node metastases and was 
treated with 400 mg bid continuously. 
 
Patients with tumors harboring mutations in PIK3CA (Part C) 
At the final analysis, 31 patients with PIK3CA-mutant breast cancer (Cb cohort) and 28 
patients with PIK3CA-mutant gynecologic cancer (Cg cohort) had received AZD5363, of 
whom 54 were included in the main tumor response analysis set. Of patients included in 
the analysis set (excluding 3 patients with no evaluable follow-up assessments), 12/26 
(46%) and 14/25 (56%) showed a reduction in size of their tumors in the Cb and Cg 
cohorts, respectively (Figure 4B). The corresponding confirmed RECIST responses at 
final analysis were 1/28 (4%) and 2/26 (8%), respectively. The observations at the 
interim assessment (scheduled when 20 patients had been dosed and had the 
opportunity to reach 12 weeks of treatment for each cohort) showed a RECIST response 
rate of ≤20% for a single agent and therefore met the criteria to stop further recruitment. 
Results of PIK3CA mutational analysis in tissue and ctDNA and other exploratory 
biomarkers (eg PTEN status, ESR1 mutation status) are shown in Figure 4A and 
Supplementary Table 4 and described in detail in the supplementary material.   
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The safety profile of AZD5363 in Part C, which is described in detail in the 
supplementary material, was consistent with the findings in Parts A and B. 
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Discussion 
This first-in-human study assessed the safety and tolerability of AZD5363 and identified 
a recommended dosing schedule for further clinical evaluation. The study also explored 
single-agent activity of AZD5363 in populations of patients who had metastatic breast 
and gynecologic cancers with PIK3CA mutations.  
 
DLTs of AZD5363 in the dose-escalation part of our study (Part A) were skin rash, 
diarrhea, and hyperglycemia. Whereas skin rash and diarrhea were predominant in the 
continuous schedule, hyperglycemia associated with the period of Cmax was predominant 
in the intermittent 2/7 schedule, where highest AZD5363 exposures were achieved. The 
cases of skin rash and diarrhea were self-limiting and recovered once treatment 
stopped. These AEs have been noted in Phase 1 studies of other AKT inhibitors, such 
as the allosteric inhibitor MK2206 or kinase inhibitors such as GSK2141795 and 
ipatasertib (GDC-0068) (1, 12-17). Hyperglycemia development was acute and 
indicative of the inhibitory effect of AZD5363 on AKT, a key regulator of glucose 
transport and metabolism in peripheral tissues and the liver (17). No patients had ketotic 
or non-ketotic hyperosmolar coma. However, patients with diabetes were excluded from 
our study and it is not possible to rule out these complications in a diabetic population. A 
number of patients with hyperglycemia were treated with metformin according to a 
protocol-defined algorithm; however, the efficacy of this intervention requires further 
study. 
 
The trough concentrations predicted to provide efficacy based on preclinical modeling 
were exceeded in patients receiving intermittent schedules. PD analyses in PRP showed 
levels of target inhibition that were consistent with PoM in pre- and post-biopsies from 12 
patients. Owing to the limited sample size, no formal statistical testing relating to the PD 
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changes in tumor tissue was done. Collectively, the toxicity, PK, and PD data, critical 
aspects of the pharmacologic audit trail (18), have been used to select the dose of 480 
mg bid intermittent 4/7 for Part C expansion and as the recommended Phase 2 dose 
and schedule of AZD5363 monotherapy.   
  
Proof-of-principle responses were observed in the dose-escalation phase of our study 
(eg PIK3CA E545K mutant cervical cancer). Within the PIK3CA expansion cohorts, a 
number of patients showed regression of their tumors (46% in breast cancer and 56% in 
gynecologic cancers; Figure 4B). However, the RECIST response rates in the two 
expansion cohorts of patients with PIK3CA mutations in ER+ breast cancer and 
gynecologic cancers were modest (4% and 8%, respectively). Several considerations 
should be made. PIK3CA mutational status can ‘change’ upon disease recurrence 
(supplementary material and Supplementary Figure 3), reflecting intra-tumoral 
heterogeneity and clonal selection (19, 20), and studies on the role of PIK3CA as a 
predictive biomarker of PI3K pathway inhibitors have not been conclusive (21). 
Molecular analyses using different platforms revealed interesting differences of PIK3CA 
mutations seen in the archival tumor tissue and ctDNA at baseline. Results have been 
detailed in the supplementary material and Supplementary Table 4. To our knowledge, 
this is the first report of the evaluation of an AKT inhibitor in dedicated PIK3CA-mutation-
positive breast and gynecologic cancers as a single agent. For example, PIK3CA 
mutations were not a requirement while evaluating the AKT inhibitor perifosine, which 
underwent Phase 2 trials in breast cancer and showed 0/18 responses (22), or the 
allosteric AKT MK2206 in breast cancer (1/20 responses) (23) and endometrial cancer 
(0/18 responses) (24). More recently, the Phase 1 trial of ipatasertib in solid tumors 
reported no RECIST responses, although there were minor degrees of tumor regression 
(16), and no trials evaluating the drug as a single agent in breast or gynecologic cancers 
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are reported. Encouraging early response rates of the use of AZD5363 (6/21, 28%) with 
the schedules recommended in this study have been reported (25). Further efforts to 
improve outcomes by combining AZD5363 with fulvestrant in AKT-mutant breast cancer 
is ongoing. 
 
Rewiring of signal transduction pathways and clonal evolution are critical mechanisms of 
resistance, and combination therapy is almost inevitably necessary (26, 27). For 
example, the approved PI3K pathway (mTOR) inhibitor everolimus had modest clinical 
efficacy when used as a single agent in breast cancer (28). We consider the tumor 
shrinkage caused by AZD5363 as a single agent in a significant number of patients in 
the PIK3CA-mutant cohorts to be an encouraging proof of concept and the basis for 
evaluation of the drug in combination therapy. Our Phase 1 study has optimized multiple 
intermittent regimens in order to provide flexibility in the use of such a novel agent in 
combination with multiple standard-of-care or experimental agents (29).   
 
Combination of AKT inhibitors with chemotherapy is hypothesized to abrogate anti-
apoptotic effects of activation of AKT following treatment with chemotherapeutic agents 
such as cisplatin and paclitaxel. Combinations of AKT inhibitors with targeted agents 
include combinations with MEK inhibitors to overcome feedback signaling loops, 
combinations with PARP inhibitors to reduce effective homologous recombination, and 
combinations with hormonal agents such as fulvestrant and abiraterone in estrogen- and 
androgen-driven breast and prostate cancer, respectively (1).  
 
To conclude, our research identified an optimal dose and schedule for use in 
subsequent multiple Phase 2 studies evaluating AZD5363, eg AZD5363 in combination 
with chemotherapy (NCT02423603, NCT01625286) or hormonal therapy 
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(NCT02077569) in breast cancer, with olaparib in ovarian cancer (NCT02338622), and 
with enzalutamide in prostate cancer (NCT02525068). Results of these trials are now 
awaited.    
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Tables 
Table 1. Patient demographics and baseline clinical characteristics in Parts A, B, 
and C 
 Patients in Parts A and B 
(n=90) 
Patients in Part C 
(n=59) 
Mean age (SD), years  55.4 (10.8) 56.7 (12.7) 
Male:female, n 51:39 2:57 
Primary tumor location, n (%) 
Rectal/colorectal  
Pleura 
Lung 
Cervix 
Colon 
Ovary 
Breast 
Uterus 
Other
a
 
 
26 (29) 
7 (8) 
6 (7) 
5 (6) 
5 (6) 
4 (4) 
4 (4) 
0 
33 (37) 
 
NA 
NA 
NA 
9 (15) 
NA 
6 (10) 
31 (53) 
10 (17) 
3 (5) 
WHO performance status, n (%) 
 0  
 1 
 
38 (42) 
52 (58) 
 
30 (51) 
29 (43) 
Prior anticancer regimens, n (%)  
0 regimens 
1 regimen 
2 regimens 
≥3 regimens 
 Mean number of regimens (SD) 
 
0 
12 (13) 
27 (30) 
51 (57) 
3.3 (2) 
 
1 (2) 
6 (10) 
11 (19) 
41 (70) 
5.0 (3) 
30 
 
a
Other includes cancers that occurred in one or two patients. NA, not available  
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Table 2. Adverse events with frequency ≥15% irrespective of causality for Parts A and B in total or Part C in total  
Number 
(%) of 
patients 
Parts A and B Part C 
Schedule 1 (continuous) Schedule 2 (4/7) Schedule 2 (2/7) 
Total 
(N=90) 
480 mg 
bid; 4/7 
(n=59) 
80 mg 
bid 
(n=5) 
160 mg 
bid 
(n=5) 
240 mg 
bid 
(n=6) 
320 mg 
bid 
(n=12) 
400 mg 
bid 
(n=11) 
480 mg 
bid 
(n=6) 
600 mg 
bid 
(n=2) 
480 mg 
bid 
(n=11) 
640 mg 
bid 
(n=10) 
640 mg 
bid 
(n=8) 
800 mg 
bid 
(n=14) 
Patients with 
any AE 
5 
(100) 
5 
(100) 
6 
(100) 
12 
(100) 
11 
(100) 
6 
(100) 
2 
(100) 
11 
(100) 
10 
(100) 
8 
(100) 
14 
(100) 
90 
(100) 
59  
(100) 
Diarrhea 1 
(20) 
1 
(20) 
4 
(67) 
11 
(92) 
11 
(100) 
6 
(100) 
2 
(100) 
9 
(82) 
9 
(90) 
4 
(50) 
12 
(86) 
70 
(78) 
47  
(80) 
Nausea  0 
(0) 
2 
(40) 
1 
(17) 
8 
(67) 
4 
(36) 
5 
(83) 
2 
(100) 
5 
(45) 
7 
(70) 
3 
(38) 
7 
(50) 
44 
(49) 
33  
(56) 
Vomiting  0 
(0) 
1 
(20) 
2 
(33) 
5 
(42) 
4 
(36) 
3 
(50) 
1 
(50) 
5 
(45) 
5 
(50) 
3 
(38) 
6 
(43) 
35 
(39) 
26  
(44) 
Fatigue 1 
(20) 
2 
(40) 
2 
(33) 
5 
(42) 
3 
(27) 
2 
(33) 
2 
(100) 
3 
(27) 
2 
(20) 
4 
(50) 
7 
(50) 
33 
(37) 
24 
(41) 
Decreased 
appetite 
1 
(20) 
0 
(0) 
1 
(17) 
2 
(17) 
5 
(45) 
3 
(50) 
0 
(0) 
3 
(27) 
5 
(50) 
1 
(13) 
5 
(36) 
26 
(29) 
25  
(42) 
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Hyper-
glycemia 
2 
(40) 
1 
(20) 
0 
(0) 
0 
(0) 
4 
(36) 
3 
(50) 
1 
(50) 
4 
(36) 
4 
(40) 
2 
(25) 
5 
(36) 
26 
(29) 
24  
(41) 
Maculo-
papular 
rash 
1 
(20) 
2 
(40) 
1 
(17) 
3 
(25) 
3 
(27) 
3 
(50) 
2 
(100) 
3 
(27) 
1 
(10) 
1 
(13) 
4 
(29) 
24 
(27) 
15  
(25) 
Consti-
pation 
1 
(20) 
0 
(0) 
2 
(33) 
4 
(33) 
4 
(36) 
0 
(0) 
0 
(0) 
1 
(9) 
1 
(10) 
2 
(25) 
2 
(14) 
17 
(19) 
10  
(17) 
Abdominal 
pain 
0 
(0) 
0 
(0) 
1 
(17) 
5 
(42) 
2 
(18) 
2 
(33) 
0 
(0) 
2 
(18) 
0 
(0) 
3 
(38) 
0 
(0) 
15 
(17) 
16  
(27) 
Pyrexia 1 
(20) 
1 
(20) 
1 
(17) 
2 
(17) 
1 
(9) 
3 
(50) 
2 
(100) 
1 
(9) 
3 
(30) 
0 
(0) 
0 
(0) 
15 
(17) 
6  
(10) 
Headache 0 
(0) 
1  
(20) 
1  
(17) 
2  
(17) 
1  
(9) 
1 
(17) 
0  
(0) 
2 
(18) 
1 
(10) 
0  
(0) 
0 
(0) 
9 
(10) 
15  
(25) 
Anemia 0  
(0) 
0  
(0) 
1 
(17) 
0  
(0) 
1 
(9) 
0  
(0) 
0 
(0) 
2 
(18) 
1 
(10) 
2 
(25) 
0 
(0) 
7 
(8) 
12  
(20) 
Increased 
blood 
creatinine 
0  
(0) 
1 
(20) 
0  
(0) 
1 
(8) 
3 
(27) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
1 
(13) 
0  
(0) 
6  
(7) 
10  
(17) 
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Proteinuria 0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
1 
(9) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
1  
(1) 
13  
(22) 
Asthenia 0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0)  
0  
(0)  
0  
(0) 
0  
(0)  
0  
(0)  
0  
(0) 
12 
 (20) 
Hypomag-
nesemia 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0)  
0  
(0)  
0  
(0) 
0  
(0)  
0  
(0)  
0  
(0) 
9 
(15) 
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Figure legends 
Figure 1. Multiple-dose PK of AZD5363 (Day 8 of continuous schedule, Day 4 of 
4/7, and Day 2 of 2/7 intermittent schedules). A) AUC dosimetry; B) geometric 
mean (±SD) plasma concentration versus time  
Int, intermittent; SD, standard deviation 
 
Figure 2. Assessment of PD markers in PRP and paired tumor biopsies following 
treatment with AZD5363. A) Percentage change from baseline in pThr246 PRAS40 
and pSer9 GSK3β markers in PRP at 4 hours post-dose. B) Temporal change in 
pPRAS40 and pGSK3β in PRP 
In A) and B), percentage change in pPRAS40 and pGSK3β in PRP after a single dose of AZD5363 is 
shown. Data shown are from Parts A and B only (PD population) and where a result is available for 
one biomarker or the other. A) Data for each biomarker are ranked in order of descending percentage 
change and ranking is conducted for each biomarker separately. X indicates missing data. B) 
Percentage change from baseline in PD markers at various time points after 480 mg single dose 
(includes all dosing schedules). Samples failing quality control or evaluated as of poor quality, as well 
as one outlier value for pGSK3β at Cycle 0, Day 3, 0 hours post-dose, were excluded. Horizontal line, 
median; diamond, mean; box, quartile 1 to quartile 3; whiskers extend from the quartiles to the most 
extreme observation within 1.5xIQR. Outliers (>1.5xIQR) are individually displayed. C, cycle; D, day; 
IQR, interquartile range 
 
Figure 3. A) Comprehensive assessment of PD activity of AZD5363 in paired tumor 
biopsies from 12 patients by immunohistochemistry. B) PoM on tumor paired 
biopsies for pPRAS40 and pGSK3b as proximal indicators of AZD5363 target 
engagement and therefore selected as the key PoM markers 
A) Total H scores for evaluable pairs are shown for each biomarker (average of 3 non-consecutive 
tissue sections; details in supplementary material). For Foxo3a/Foxo, the percentage of positive 
nuclei is shown. Asterisks indicate the patient for whom representative staining images are shown. B) 
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The percentage change is based on the average H score for individual biomarkers in baseline and on-
treatment biopsies from three non-consecutive tissue sections. Each pair of bars represents data from 
an individual patient; tumor type is indicated in the table (left). X indicates missing data. *KRAS-
mutant colorectal cancer; 
†
PIK3CA E545K mutant cervical cancer (this patient was enrolled in Study 1 
Part C). cont, continuous 
 
Figure 4. Waterfall plots of best percentage change in target lesion size from 
baseline in patients from A) Parts A and B and B) Part C, with associated 
molecular data 
A) Exploratory mutation analysis by Sequenom in patients who provided suitable archival tumor 
tissue, who had baseline tumor assessment, and for whom best percentage change could be 
calculated. Mutations of potential interest in relationship to modulation of response to AZD5363 or 
known oncogenic drivers are shown. The AKT1 mutation detected in one patient was Q43X. B) 
Progression-free survival (PFS), PIK3CA-mutation status by local testing (tissue), central testing 
(cobas
®
 PCR, tissue and plasma), and PTEN status (immunohistochemistry, tissue) are shown. Only 
patients with baseline tumor assessment and measurable disease and for whom best percentage 
change could be calculated are included in the plot. The type of tissue used for central and 
exploratory assessment is indicated (M=metastatic, P=primary). Additional exploratory data on 
PIK3CA and ESR1 mutations testing in ctDNA by ddPCR are described in Supplementary Table 4 
(including time lapse between tissue biopsy and plasma collection) and in the supplementary material 
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Figure 1  
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Figure 2  
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